Compare CRVO & GRF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRVO | GRF |
|---|---|---|
| Founded | 2001 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.7M | 43.9M |
| IPO Year | 2011 | N/A |
| Metric | CRVO | GRF |
|---|---|---|
| Price | $3.92 | $10.00 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $23.00 | N/A |
| AVG Volume (30 Days) | ★ 43.9K | 1.8K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 3.70% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.16 |
| Revenue | ★ $4,006,510.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.71 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.51 | $9.25 |
| 52 Week High | $13.13 | $11.85 |
| Indicator | CRVO | GRF |
|---|---|---|
| Relative Strength Index (RSI) | 41.98 | 44.11 |
| Support Level | $3.55 | $9.60 |
| Resistance Level | $4.41 | $10.83 |
| Average True Range (ATR) | 0.31 | 0.17 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 35.56 | 43.86 |
CervoMed Inc is a clinical stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
Eagle Capital Growth Fund Inc is a diversified closed-end investment company. The fund's objective is long-term growth utilizing the concept of total return for selecting investments. It seeks to achieve its investment objectives by investing predominantly in U.S. issuer common stock by giving preference to high-quality companies, where high quality denotes substantial operating income margins, high returns on capital, and robust balance sheets.